Clinical Trials on Respiratory Syncytial Virus Infections in Australia

Total 1126 results

Clover Biopharmaceuticals AUS Pty Ltd

Recruiting

First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

Respiratory Syncytial Virus Infection

Australia
Ark Biosciences Inc.

Terminated

A Study of AK0529 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

Australia
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection

Australia
Shanghai Ark Biopharmaceutical Co., Ltd.
Ark Biosciences Pty Ltd.

Completed

Viral Inhibition in Children for Treatment of RSV (VICTOR)

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Australia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Biota Scientific Management Pty Ltd

Completed

Safety Study of Oral BTA9881 to Treat RSV Infection

Respiratory Syncytial Virus Infections

Australia
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection | Metapneumovirus Infection

Australia, United States
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Active, not recruiting

Safety and Efficacy of BARS13 in the Elderly

Respiratory Syncytial Virus Infections

Australia
Gilead Sciences

Completed

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Infection

Korea, Republic of, Australia, Israel, New Zealand, Netherlands, United States, France, United Kingdom, Italy, Belgium, Poland
Ark Biosciences Inc.

Completed

Safety, Tolerability and PK Study of AK0529 in Healthy Human

Respiratory Syncytial Virus Infections

Australia
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Completed

A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants

Respiratory Syncytial Virus Infections

Australia
Gilead Sciences

Completed

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus (RSV)

United States, Belgium, Canada, Netherlands, Australia, Germany, United Kingdom, France
Gilead Sciences

Withdrawn

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

Australia
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
Codagenix, Inc

Completed

Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers

Respiratory Syncytial Virus Infections

Australia
Ablynx

Completed

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

Respiratory Syncytial Virus Infection

Australia, Belgium, Bulgaria, Estonia, Hungary, Israel, Latvia, Malaysia, Philippines, Poland, Slovakia, Spain, Thailand, United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Alnylam Pharmaceuticals

Completed

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

United States, Australia, Austria, Canada, France, Germany
Pfizer

Completed

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

Respiratory Syncytial Virus

Australia
Ablynx

Withdrawn

Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Belgium, Spain, Australia
Alnylam Pharmaceuticals

Completed

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

United States, Australia
Janssen Sciences Ireland UC

Terminated

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA)

Respiratory Syncytial Virus Infections

United States, Belgium, Taiwan, Israel, Japan, Argentina, Malaysia, Korea, Republic of, Netherlands, Spain, Australia, Italy, Brazil, France, United Kingdom, Sweden, Bulgaria
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia
ModernaTX, Inc.

Active, not recruiting

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Respiratory Syncytial Virus | Human Metapneumovirus

Spain, United Kingdom, Canada, Australia, United States, South Africa, Poland, Colombia, Argentina, Latvia, Panama
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

Australia, Singapore, United States, New Zealand, Taiwan
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Japan, Spain, Korea, Republic of, Canada, Germany
Merck Sharp & Dohme LLC

Recruiting

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

RSV Infection

United States, Australia, Canada, Chile, Colombia, Germany, Greece, Malaysia, Mexico, New Zealand, Puerto Rico, Singapore, South Africa, Spain, Taiwan, Turkey, United Kingdom, Japan, Peru, Hong Kong, France, Thailand, Finland, Hungary, ... and more
Enanta Pharmaceuticals, Inc

Recruiting

A Study to Evaluate EDP 938 Regimens in Children With RSV (RSVPEDs)

Respiratory Syncytial Virus (RSV)

United States, Spain, Israel, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, Argentina, Brazil, New Zealand, Poland, Romania, South Africa, Mexico
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Respiratory Syncytial Virus Infections

United States, Australia, Germany, Czechia
Gilead Sciences

Completed

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Respiratory Syncytial Virus

Korea, Republic of, Taiwan, Israel, United States, France, Singapore, Sweden, Australia, Canada, United Kingdom, Brazil, Germany, Netherlands, Spain, Switzerland
Janssen Sciences Ireland UC

Terminated

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Virus Diseases | Respiratory Syncytial Virus Infections

Australia, Spain, Belgium, Sweden, Netherlands, Brazil, Germany, Argentina, Philippines, United States
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
Abbott

Completed

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Severe Respiratory Syncytial Virus Infection

Austria, Belgium, France, Germany, Italy, Norway, Poland, Slovenia, Spain, United Kingdom
GlaxoSmithKline

Completed

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

Respiratory Syncytial Virus Infections

United States, Spain, Canada, Finland, Panama, South Africa, New Zealand, Australia, France
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

Respiratory Syncytial Virus

United States, Spain, Taiwan, Korea, Republic of, Singapore, Canada, Belgium, Finland, Japan, United Kingdom, Chile, New Zealand, South Africa, Australia, Puerto Rico, Argentina, Costa Rica, Poland, Bangladesh, Colombia, Germany, ... and more
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

Canada, Australia, United States, Germany, Japan, South Africa
Janssen Research & Development, LLC

Terminated

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

Australia, France, United Kingdom, Belgium, Taiwan, United States, Spain, Argentina, Mexico, Bulgaria, Malaysia, Japan, Sweden, Korea, Republic of, Canada, Netherlands, Brazil, Germany, Poland
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
GlaxoSmithKline

Terminated

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

Respiratory Syncytial Virus Infections

United States, Australia, France, Finland, Taiwan, Spain, Philippines, Mexico, Belgium, Italy, Panama, New Zealand, Thailand, Brazil, Canada, India, Colombia, Korea, Republic of, United Kingdom, South Africa, Argentina, Bangladesh, Dominican... and more
MedImmune LLC

Completed

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Respiratory Syncytial Virus Infections | Chronic Lung Disease and <= 24 Months of Age or | Premature With Gestational Age <=35 Weeks and <=6 Months of Age

Australia, Chile, New Zealand
Janssen Research & Development, LLC

Completed

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States, Taiwan, Japan, Korea, Republic of, France, Mexico, Brazil, Sweden, Argentina, Ukraine, Canada, Spain, Germany, Poland, Belgium, Russian Federation, South Africa, Australia, Bulgaria
GlaxoSmithKline

Recruiting

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Spain, Belgium, Korea, Republic of, France, Canada, Finland, Taiwan, Thailand, Brazil, India, New Zealand, Germany, South Africa, Colombia, Panama, Philippines, Argentina, Bangladesh, Dominican Republic and more
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) (MELODY)

Respiratory Syncytial Virus Infections

United States, Finland, Spain, Belgium, France, Korea, Republic of, Turkey, Austria, New Zealand, South Africa, Australia, Germany, Bulgaria, United Kingdom, Ukraine, Argentina, Czechia, Panama, Estonia, Lithuania, Poland, Japan, Co... and more
AstraZeneca

Completed

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Respiratory Syncytial Virus Infections

United States, France, Italy, Spain, Belgium, Russian Federation, Poland, Turkey, New Zealand, Austria, Korea, Republic of, Germany, Hungary, Bulgaria, Ukraine, South Africa, Japan, Estonia, Lithuania, United Kingdom, Canada, Czechia and more
GlaxoSmithKline

Active, not recruiting

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Canada, Spain, Finland, Germany, Japan, Estonia, Belgium, South Africa, Korea, Republic of, Italy, Russian Federation, Australia, Mexico, United Kingdom, New Zealand, Poland
Technovalia, Pty Ltd
Chulalongkorn University; Southern Star Research Pty Ltd.; BioNet-Asia

Active, not recruiting

Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

COVID-19, SARS CoV 2 Infection

Australia
DiaSorin Molecular LLC

Not yet recruiting

LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

Coronavirus Disease 2019 | Influenza A | Respiratory Syncytial Virus (RSV) | Adenovirus | Influenza Type B | Enterovirus | Mycoplasma Pneumonia | Bordetella Parapertussis Infection | Chlamydia Pneumonia | Para Influenza | Bordetella Pertussis Infection, Respiratory

Australia
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Influenza

Australia, Singapore
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Respiratory Syncytial Virus Infections

United States, Australia, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Hungary, Netherlands, New Zealand, Panama, Puerto Rico, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
Seqirus

Completed

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

Influenza

Australia

Clinical Trials on Respiratory Syncytial Virus Infections in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations